Open AccessPD-L1 expression and prognostic impact in glioblastoma
Author(s) -
Edjah K. Nduom,
Jun Wei,
Nasser K. Yaghi,
Neal Huang,
Ling Yuan Kong,
Konrad Gabrusiewicz,
Xiaoyang Ling,
Shouhao Zhou,
Cristina Ivan,
Jie Qing Chen,
Jared K. Burks,
Gregory N. Fuller,
George A. Calin,
Charles A. Conrad,
Caitlin Creasy,
Krit Ritthipichai,
Laszlo G. Radvanyi,
Amy B. Heimberger
Publication year - 2015
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/nov172
Subject(s) - flow cytometry , immunohistochemistry , ex vivo , cytotoxic t cell , medicine , pd l1 , biomarker , glioblastoma , oncology , immune system , cancer research , t cell , cancer , in vivo , immunotherapy , pathology , biology , immunology , in vitro , biochemistry , microbiology and biotechnology
Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2 trials are ongoing in glioblastoma (GBM). Previous reports have suggested that responses are more frequent in patients with tumors that express PD-L1; however, this has been disputed. At issue is the validation of PD-L1 biomarker assays and prognostic impact.